Fluperlapine (NB 106 689), a dibenzazepine chemically and pharmacologically similar to clozapine, was investigated in 28 patients with regard to antipsychotic efficacy and occurrence of adverse effects. In an open early phase II study patients were given fluperlapine over a period of 26 days. The average daily dosage was 300 mg. Five patients had to be withdrawn from the trial during the first week due to side effects or therapeutic inefficacy, 23 patients were examined during the period planned. The substance proved to have fast-acting antipsychotic effect with few adverse effects and no extrapyramidal motor disturbances.
The Andreasen Scale (SANS), an instrument for evaluating negative symptoms in schizophrenic patients, was translated at the Psychiatric Hospital of Munich and tested on 35 chronic schizophrenic inpatients at the Regensburg State Mental Hospital. In addition, psychopathology was evaluated with the BPRS, sociodemographic data were collected, and cognitive performance was evaluated by the MMS. Also, VBR was determined on the basis of CAT scans. Our results suggest that the SANS is a reliable instrument for measuring negative symptoms; however, the symptom complexes are affected by age, duration of illness and hospitalization, thus making a clear distinction between negative symptoms per se and the effects of hospitalization questionable.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.